CYTK

51.94

3.42% 1.72

Handel nachbörslich: 51.94

Cytokinetics Inc (CYTK)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CYTK? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$50.22

Offen:

$50.24

24-Stunden-Volumen:

1.28M

Relative Volume:

1.11

Marktkapitalisierung:

$6.11B

Einnahmen:

$3.13M

Nettoeinkommen (Verlust:

$-545.28M

KGV:

-9.4094

EPS:

-5.52

Netto-Cashflow:

$-401.27M

1W Leistung:

-11.40%

1M Leistung:

-5.51%

6M Leistung:

-12.75%

1J Leistung:

+60.11%

1-Tages-Spanne:

$49.64

$52.01

1-Wochen-Bereich:

$49.64

$58.95

52-Wochen-Spanne:

$30.68

$110.25

Cytokinetics Inc Stock (CYTK) Company Profile

Firmenname

Cytokinetics Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

(650) 624-3000

Adresse

350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA

Mitarbeiter

564

Twitter

@Cytokinetics

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

CYTK's Discussions on Twitter

Vergleichen Sie CYTK mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CYTK	51.94	6.11B	3.13M	-545.28M	-401.27M	-5.52
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-01-24	Herabstufung	UBS	Buy → Neutral
2024-01-05	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2023-11-09	Eingeleitet	Goldman	Buy
2023-11-07	Eingeleitet	B. Riley Securities	Buy
2023-08-15	Eingeleitet	SVB Securities	Outperform
2023-02-17	Eingeleitet	BofA Securities	Neutral
2022-12-23	Bestätigt	Needham	Buy
2022-12-20	Eingeleitet	Truist	Buy
2022-10-11	Eingeleitet	UBS	Buy
2022-01-28	Eingeleitet	Goldman	Buy
2021-12-22	Eingeleitet	Oppenheimer	Outperform
2021-12-10	Eingeleitet	JP Morgan	Overweight
2021-10-07	Eingeleitet	Jefferies	Buy
2021-03-12	Eingeleitet	Wolfe Research	Outperform
2021-02-18	Eingeleitet	Barclays	Overweight
2021-01-20	Bestätigt	H.C. Wainwright	Buy
2020-10-29	Eingeleitet	Goldman	Neutral
2020-07-10	Eingeleitet	Raymond James	Strong Buy
2020-05-05	Eingeleitet	Mizuho	Buy
2020-04-09	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2018-09-21	Eingeleitet	Cantor Fitzgerald	Overweight
2018-09-10	Fortgesetzt	Morgan Stanley	Equal-Weight
2017-11-22	Bestätigt	Morgan Stanley	Overweight
2017-11-22	Herabstufung	Needham	Strong Buy → Buy
2017-11-21	Bestätigt	H.C. Wainwright	Buy
2017-07-31	Eingeleitet	Morgan Stanley	Overweight
2017-03-08	Eingeleitet	Rodman & Renshaw	Buy
2017-02-06	Hochstufung	Needham	Buy → Strong Buy
2016-12-16	Eingeleitet	Cantor Fitzgerald	Overweight
2016-07-28	Bestätigt	Needham	Buy
2015-11-10	Bestätigt	FBR Capital	Outperform
2015-11-09	Bestätigt	ROTH Capital	Buy
2015-07-24	Bestätigt	MLV & Co	Buy
2014-12-31	Bestätigt	ROTH Capital	Buy
2014-11-04	Hochstufung	MLV & Co	Hold → Buy
2014-04-28	Bestätigt	Needham	Buy

Alle ansehen

Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten

10:12 AM

H.C. Wainwright keeps Buy rating on Cytokinetics shares, citing promising data on aficamten and omecamtiv - Investing.com Canada

10:12 AM

08:32 AM

Cytokinetics' (CYTK) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

08:32 AM

Nov 16, 2024

Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024 - Yahoo Finance

Nov 16, 2024

Principal Financial Group Inc. Sells 120,497 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat

Nov 16, 2024

Nov 15, 2024

Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024 - Marketscreener.com

Nov 15, 2024

Nov 14, 2024

Significant Portfolio Addition: T. Rowe Price Investment Managem - GuruFocus.com

Nov 14, 2024

Insider Sale at Cytokinetics Inc (CYTK): EVP Research & Developm - GuruFocus.com

Nov 14, 2024

Cytokinetics: On The Cusp Of Commercialization (NASDAQ:CYTK) - Seeking Alpha

Nov 14, 2024

Nov 13, 2024

Cytokinetics EVP sells $370,880 in stock By Investing.com - Investing.com Nigeria

Nov 13, 2024

Cytokinetics EVP sells $370,880 in stock - Investing.com

Nov 13, 2024

Cytokinetics' SWOT analysis: cardiac drug maker's stock poised for growth - Investing.com

Nov 13, 2024

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives $83.67 Average Price Target from Brokerages - MarketBeat

Nov 13, 2024

Nov 12, 2024

FMR LLC Bolsters Stake in Cytokinetics Inc - GuruFocus.com

Nov 12, 2024

Cytokinetics to Present at Jefferies London Healthcare Conference 2024 | CYTK Stock News - StockTitan

Nov 12, 2024

Lisanti Capital Growth LLC Sells 26,800 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat

Nov 12, 2024

Nov 11, 2024

Cytokinetics Launches Phase 1 Trial for Novel Muscle Function Drug CK-089 | CYTK Stock News - StockTitan

Nov 11, 2024

HC Wainwright Forecasts Reduced Earnings for Cytokinetics - MarketBeat

Nov 11, 2024

Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4015089 - Marketscreener.com

Nov 11, 2024

Nov 10, 2024

Van ECK Associates Corp Has $3.80 Million Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat

Nov 10, 2024

Nov 08, 2024

Cytokinetics started at outperform by RBC, valuation cited - MSN

Nov 08, 2024

Eyeing drug launch in 2025, Cytokinetics rolls out HCM awareness campaign - MM+M Online

Nov 08, 2024

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga

Nov 08, 2024

Cytokinetics (NASDAQ:CYTK) Now Covered by Analysts at Royal Bank of Canada - MarketBeat

Nov 08, 2024

Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

Cytokinetics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 08, 2024

Nov 07, 2024

Cytokinetics: Q3 Earnings Snapshot - AOL

Nov 07, 2024

Cytokinetics director resigns, board reduced to eight By Investing.com - Investing.com UK

Nov 07, 2024

Cytokinetics (NASDAQ:CYTK) Posts Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat

Nov 07, 2024